Donated Antibodies Working Against nCoV

PHASE2CompletedINTERVENTIONAL
Enrollment

483

Participants

Timeline

Start Date

May 2, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Convalescent Plasma

"4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design."

DRUG

Standard of care

Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.

Trial Locations (21)

1000

Institut Bordet, Brussels

UMC Sint-Pieter, Brussels

1030

CHU Brugmann, Brussels

1070

Erasmus Ziekenhuis, Brussels

1090

UZ Brussel, Brussels

1200

Cliniques Universitaires St Luc, Brussels

2050

ZNA, Antwerp

2820

Imelda Ziekenhuis Bonheiden, Bonheiden

3000

UZ Leuven, Leuven

3800

Sint-Trudo Ziekenhuis, Sint-Truiden

4000

CHC Liège Mont Légia, Liège

CHR Citadelle Liège, Liège

CHU Liège Sart-Tilman, Liège

7000

CHU Ambroise Paré, Mons

7100

CHR Jolimont Mons-Hainaut, Mons

7500

Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai

8500

AZ Groeninge, Kortrijk

8800

AZ Delta, Roeselare

9000

AZ Maria Middelares, Ghent

AZ Sint-Lucas, Ghent

9800

AZ Sint-Vincentius, Deinze

All Listed Sponsors
collaborator

Federal Knowledge Centre (KCE)

UNKNOWN

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT04429854 - Donated Antibodies Working Against nCoV | Biotech Hunter | Biotech Hunter